Biopure, the disgraced developer of a failed human blood substitute, is attempting a comeback. It’s a biotech resurrection that seems quixotic at best. Delusional might be more accurate, given the company’s previous immolation.
On Wednesday, Hemoglobin Oxygen Therapeutics filed a registration statement with the Securities and Exchange Commission, seeking to raise $30 million through an initial public offering. The company name is new, but the blood substitute products it seeks to develop — Hemopure and Oxyglobin — originated with Biopure, which blew up in the mid-2000s and filed for bankruptcy in 2009.
Honestly, I love the idea, but not because I believe Hemoglobin Oxygen Therapeutics is going to turn out any better than Biopure. For me, this is more about nostalgia.
Exciting news! STAT has moved its comment section to our subscriber-only app, STAT+ Connect. Subscribe to STAT+ today to join the conversation or join us on Twitter, Facebook, LinkedIn, and Threads. Let's stay connected!
To submit a correction request, please visit our Contact Us page.